Glanzmann thrombasthenia (GT) is a rare inherited blood clotting (coagulation) disorder characterized by the impaired function of specialized cells (platelets) that are essential for proper blood clotting. Symptoms of this disorder usually include abnormal bleeding, which may be severe.
Prolonged untreated or unsuccessfully treated hemorrhaging associated with Glanzmann thrombasthenia may be life threatening.
This study aims to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of a new investigational medication for patients with Glanzmann Thrombasthenia.
Participant eligibility criteria
- Patients aged 18 to 67 years.
- Confirmed diagnosis of Glanzmann thrombasthenia.
